Prostate Cancer|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofProstate Cancer Prostate Cancer

Prostate cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen.

The prostate is below the bladder (the hollow organ where urine is stored) and in front of the rectum (the last part of the intestines). Just behind the prostate are glands called seminal vesicles that make most of the fluid for semen. The urethra, which is the tube that carries urine and semen out of the body through the penis, goes through the center of the prostate.

The size of the prostate can change as a man ages. In younger men, it is about the size of a walnut, but it can be much larger in older men.

Types of prostate cancer

Almost all prostate cancers are adenocarcinomas. These cancers develop from the gland cells (the cells that make the prostate fluid that is added to the semen).

Other types of cancer that can start in the prostate include:

1.Small cell carcinomas

2.Neuroendocrine tumors (other than small cell carcinomas)

3.Transitional cell carcinomas

4.Sarcomas

These other types of prostate cancer are rare. If you are told you have prostate cancer, it is almost certain to be an adenocarcinoma.

Some prostate cancers grow and spread quickly, but most grow slowly. In fact, autopsy studies show that many older men (and even some younger men) who died of other causes also had prostate cancer that never affected them during their lives.

Cat. No.	Product Name	CAS No.	Information
H9343	Onilcamotide	1164096-85-8	Onilcamotide is a cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC,Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities; Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.
H9300	ARV-110	2222112-77-6	ARV-110(Bavdegalutamide) is a first-in-class PROTAC that effectively targets the wild type Androgen Receptor (AR) and certain genomic alterations of the AR (amplification, T878A, H875Y, F877L, M895V, but not L702H or AR-V7) for degradation in both enzalutamide sensitive and resistant preclinical models;ARV-110 showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC).
H9009	Vipivotide tetraxetan	1702967-37-0	Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM.
H8857	Rezvilutamide	1572045-62-5	Rezvilutamide is a potnet androgen receptor inhibitor,inhibit prostate cancer in a more effective manner.
H8124	TAS-115	1190836-34-0	Pamufetinib is a potent, dual VEGFR2/c-Met inhibitor with IC50 of 30 and 32 nM against rVEGFR2 and rMET, respectively; also inhibits PDGFRα/β, Axl, c-Kit, Src, FLT-1 in a 192-kinase panel assay; markedly inhibits the tyrosine phosphorylation of VEGFR2 at 10 nM in VEGF-stimulated HUVECs, also inhibits the tyrosine phosphorylation of MET in MKN45 cells; inhibits cellular proliferation of HUVECs under VEGF-dependent growth condition with IC50 of 19 nM, with weak inhibition of growth (GI50>10 uM) in VEGFR signal- or MET signal-independent cells; effectively suppresses the progression of MET-inactivated tumor by blocking angiogenesis in vivo.
H7732	Masitinib mesylate	1048007-93-7	A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays; also inhibits Lyn, and to a lesser extent, FGFR3, and inhibits KIT gain-of-function mutants V559D (IC50=3.0 nM) and Δ27 mouse mutant (IC50=5 nM); dose-dependently inhibits SCF-induced cell proliferation in Ba/F3 cells expressing human wild-type KIT (IC50=150 nM); inhibits tumour growth in vivo.
H7731	Masitinib	790299-79-5	A potent tyrosine kinase inhibitor targeting c-Kit and PDGFR with IC50 of 0.15 and 0.05 uM in cell based assays; also inhibits Lyn, and to a lesser extent, FGFR3, and inhibits KIT gain-of-function mutants V559D (IC50=3.0 nM) and Δ27 mouse mutant (IC50=5 nM); dose-dependently inhibits SCF-induced cell proliferation in Ba/F3 cells expressing human wild-type KIT (IC50=150 nM); inhibits tumour growth in vivo.
H8627	Rezvilutamide	1572045-62-5	Rezvilutamide (developmental code name SHR3680) is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.As of October 2020, rezvilutamide is in phase 3 clinical trials for prostate cancer.Other structural analogues of rezvilutamide besides enzalutamide include apalutamide and proxalutamide.
H6157	ASP9521	1126084-37-4	ASP9521(ASP-9521) is a potent, selective, orally bioavailable inhibitor of Aldo-keto reductase 1C3 (17βHSD5, AKR1C3) with IC50 of 11 nM and 49 nM for recombinant human or cynomolgus monkey AKR1C3, respectively; displays >100-fold selectivity for AKR1C3 over the isoform AKR1C2, and does not inhibits AKR1C1 and AKR1C6; inhibits both aandrostenedione (10 nM)-induced PSA production and cell proliferation in LNCaPAKR1C3 cells with IC50 of 11 nM and 6.6 nM, respectively; inhibits AD-induced intratumoural T production in CWR22R xenografts.
H5931	Onapristone	96346-61-1	A synthetic, steroidal progesterone receptor (PR) antagonist with reduced antiglucocorticoid activity compared to mifepristone.

Select Your Country or Region

Request The Product List ofProstate Cancer Prostate Cancer

Request The Product List

* Indicates a Required FieldYour information is safe with us.